6,600 Shares in Myriad Genetics, Inc. (MYGN) Acquired by Wasatch Advisors Inc.
Wasatch Advisors Inc. purchased a new stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) during the 3rd quarter, according to its most recent filing with the SEC. The institutional investor purchased 6,600 shares of the company’s stock, valued at approximately $239,000.
A number of other large investors have also recently modified their holdings of MYGN. Teachers Advisors LLC grew its holdings in Myriad Genetics by 1.1% during the 1st quarter. Teachers Advisors LLC now owns 116,924 shares of the company’s stock valued at $2,245,000 after purchasing an additional 1,287 shares during the last quarter. Teachers Retirement System of The State of Kentucky bought a new position in Myriad Genetics during the 1st quarter valued at about $453,000. Bank of Montreal Can grew its holdings in Myriad Genetics by 121.2% during the 2nd quarter. Bank of Montreal Can now owns 248,085 shares of the company’s stock valued at $6,410,000 after purchasing an additional 135,935 shares during the last quarter. Aperio Group LLC grew its holdings in Myriad Genetics by 4.6% during the 2nd quarter. Aperio Group LLC now owns 12,129 shares of the company’s stock valued at $313,000 after purchasing an additional 534 shares during the last quarter. Finally, Hartford Investment Management Co. bought a new position in Myriad Genetics during the 2nd quarter valued at about $258,000.
In other news, insider Alexander Ford sold 3,031 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $31.64, for a total value of $95,900.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John T. Henderson sold 30,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $30.30, for a total transaction of $909,000.00. Following the completion of the sale, the director now directly owns 52,524 shares of the company’s stock, valued at approximately $1,591,477.20. The disclosure for this sale can be found here. 6.70% of the stock is currently owned by corporate insiders.
Several equities analysts recently commented on the stock. Cowen Inc reiterated a “hold” rating and set a $25.00 price target on shares of Myriad Genetics in a report on Sunday, September 17th. Jefferies Group LLC restated a “hold” rating and issued a $23.00 target price (up from $21.00) on shares of Myriad Genetics in a research note on Thursday, August 10th. Barclays PLC dropped their target price on shares of Myriad Genetics from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Wednesday, August 9th. Leerink Swann restated a “market perform” rating and issued a $31.00 target price on shares of Myriad Genetics in a research note on Monday, October 2nd. Finally, BidaskClub upgraded shares of Myriad Genetics from a “hold” rating to a “buy” rating in a research note on Saturday, August 12th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $28.10.
Shares of Myriad Genetics, Inc. (MYGN) opened at $33.26 on Friday. Myriad Genetics, Inc. has a 52-week low of $15.15 and a 52-week high of $37.30. The firm has a market cap of $2,302.96, a P/E ratio of 30.51, a PEG ratio of 2.11 and a beta of 0.24. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.34 and a quick ratio of 2.06.
Myriad Genetics (NASDAQ:MYGN) last announced its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.21 by $0.05. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. The firm had revenue of $190.20 million during the quarter, compared to analysts’ expectations of $183.52 million. During the same quarter in the prior year, the company earned $0.23 EPS. The company’s revenue was up 7.2% compared to the same quarter last year. research analysts expect that Myriad Genetics, Inc. will post 1.05 earnings per share for the current fiscal year.
Myriad Genetics Profile
Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.
Want to see what other hedge funds are holding MYGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myriad Genetics, Inc. (NASDAQ:MYGN).
Receive News & Ratings for Myriad Genetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.